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OBJECTIVES We sought to determine the safety and efficacy of polymer-regulated site-specific delivery of
paclitaxel in patients with diabetes mellitus undergoing stent implantation.
BACKGROUND Percutaneous coronary intervention in patients with diabetes is associated with high rates of
restenosis and repeat revascularization due to excessive neointimal proliferation, a process that
may be blunted with the site-specific delivery of paclitaxel.
METHODS In the TAXUS-IV trial, 1,314 patients were prospectively randomized to the slow rate-release
polymer-based paclitaxel-eluting TAXUS stent or the bare-metal EXPRESS stent (Boston
Scientific Corp., Natick, Massachusetts). Medically treated diabetes was present in 318
patients (24%), 105 of whom required insulin.
RESULTS Among patients with diabetes, the TAXUS stent, compared to the bare-metal stent, reduced
the rate of 9-month binary angiographic restenosis by 81% (6.4% vs. 34.5%, p 0.0001), and
reduced the 12-month rates of target lesion revascularization by 65% (7.4% vs. 20.9%, p 
0.0008), target vessel revascularization by 53% (11.3% vs. 24%, p  0.004), and composite
major adverse cardiac events by 44% (15.6% vs. 27.7%, p  0.01). The one-year rates of
cardiac death (1.9% vs. 2.5%), myocardial infarction (3.2% vs. 6.4%), and subacute thrombosis
(0.6% vs. 1.2%) were comparable between the paclitaxel-eluting and control stents, respec-
tively. In the insulin-requiring subgroup, the TAXUS stent reduced angiographic restenosis
by 82% (7.7% vs. 42.9%, p  0.0065), and reduced the one-year rate of target lesion
revascularization by 68% (6.2% vs. 19.4%, p  0.07), a relative reduction similar to patients
without diabetes.
CONCLUSIONS The site-specific delivery of paclitaxel after coronary stent implantation is highly effective in
reducing clinical and angiographic restenosis in patients with diabetes mellitus. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.075Cardiol 2005;45:1172–9) © 2005 by the American College of Cardiology Foundation
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ds many as 25% of percutaneous coronary interventions
nvolve diabetic patients (1). Compared with non-diabetics,
he prognosis in patients with diabetes after balloon angio-
lasty is poor, with a high rate of restenosis and late target
essel occlusion (2,3). Although coronary stenting signifi-
antly attenuates restenosis and target vessel revasculariza-
ion (TVR) rates in the diabetic patient compared to balloon
ngioplasty alone, the frequency and severity of in-stent
From *St. Vincent’s Hospital, Indianapolis, Indiana; †Cardiac Cath Lab Research
enter, Houston, Texas; ‡St. Mary’s Medical Center, Saginaw, Michigan; §Sinai
ospital of Baltimore, Baltimore, Maryland; Wake Forest University Baptist
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linic Foundation, Cleveland, Ohio; and ††Columbia University Medical Center and
he Cardiovascular Research Foundation, New York, New York. Drs. Hermiller,
llis, and Stone have served as consultants for Boston Scientific, and Dr. Russell is an
mployee of and equity holder in Boston Scientific. The names of the investigators,
esearch coordinators, and institutions participating in the TAXUS-IV trial appear in
eference 11.s
Manuscript received June 28, 2004; revised manuscript received October 18, 2004,
ccepted October 19, 2004.estenosis remains greater than in non-diabetics and is often
ecalcitrant, frequently requiring bypass grafting for symp-
omatic relief (4–8).
The polymer-regulated delivery of both paclitaxel and
irolimus at the site of arterial injury has been shown to
educe clinical and angiographic restenosis rates after stent
mplantation in de novo coronary lesions in a broad range of
atients (9–11). Less is known about the outcomes of these
evices in patients with diabetes. The hypothesis of the
resent study was that the site-specific delivery of paclitaxel
ould lower angiographic restenosis rates and improve
ntermediate-term clinical outcomes in medically treated
iabetic patients in the TAXUS-IV trial.
ETHODS
atient population and protocol. The TAXUS-IV study
esign has been previously described (11). Patients with
ingle de novo lesions with visually estimated lesion length
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April 19, 2005:1172–9 Paclitaxel-Eluting Stents in Diabetic Patientsetween 10 to 28 mm and reference vessel diameter 2.5 to
.75 mm coverable by a single study stent were eligible for
andomization. Major exclusion criteria have been reported
reviously (11). Of the 1,314 patients enrolled, 318 (24.2%)
ad diabetes (defined as being treated with oral hypoglyce-
ic agents or insulin at the time of admission); of these, 213
67.0% of the diabetics and 16.2% of the entire population)
eceived oral diabetic medications only, and 105 (33.0% of
he diabetics and 8.2% of the entire population) were
nsulin-requiring.
Patients were randomized to either the slow rate-release,
olymer-based, paclitaxel-eluting EXPRESS stent (the TAXUS
tent, Boston Scientific Corp., Natick, Massachusetts) or an
dentical appearing bare-metal EXPRESS stent. Random-
zation was stratified by the presence of medically treated
iabetes and vessel size (3.0 or 3.0 mm). Stents were
vailable in diameters of 2.5, 3.0, and 3.5 mm and in lengths
f 16, 24, and 32 mm. After mandatory pre-dilatation, an
ppropriate-sized stent (stent to distal reference vessel
iameter ratio of 1 to 1.1:1 and approximately 4 to 6 mm
onger than the lesion) was implanted at 12 atm. Aspirin
as administered to all patients before the procedure and
ndefinitely thereafter. Unfractionated heparin was admin-
stered per standard practice, and glycoprotein IIb/IIIa
nhibitor use was at operator discretion. Clopidogrel was
ecommended as a 300-mg loading dose before catheteriza-
ion and then was administered at 75 mg/day for at least six
onths. Clinical follow-up was scheduled at one, four, and
ine months, and yearly thereafter for five years. Angio-
Table 1. Selected Baseline Demographic and A
and Without Diabetes Mellitus
Diabetic
(n 
Clinical characteristics
Age, yrs 62.17 
Male 63.5
Hypertension 81.1
Hyperlipidemia 71.4
Prior myocardial infarction 29.9
Left ventricular ejection fraction 53.27 
Unstable angina 35.2
Target lesion coronary artery
Left anterior descending 37.7
Left circumflex 29.6
Right 32.7
Baseline angiographic features
Lesion length, mm 14.0 
Reference vessel diameter, mm 2.69 
Minimal luminal diameter, mm 0.92 
Abbreviations and Acronyms
MACE  major adverse cardiac events
MI  myocardial infarction
TLR  target lesion revascularization
TVR  target vessel revascularizationDiameter stenosis, % 66.0  11.0raphic follow-up at nine months was performed in a subset
f 559 patients, including 136 patients with diabetes, 47 of
hom were among the insulin-requiring subgroup.
ata management, end points, and definitions. All case
eport forms were verified by independent study monitors
n-site. The primary end point was the incidence of TVR
or ischemia. Major adverse cardiac events (MACE) were
efined as cardiac death, myocardial infarction (MI), or
schemia-driven TVR. Target vessel failure was defined
s death, MI, or ischemia-driven revascularization related
o the target vessel. Clinical end points were adjudicated
y an independent committee blinded to treatment allo-
ation after review of original source documentation. The
efinitions for the end points and the methodology for
heir ascertainment have been previously reported (11).
ngiographic core laboratory analysis was performed as
reviously described and blinded to clinical outcomes
11).
tatistical methods. Subset analysis of patients with dia-
etes was pre-specified in the study protocol. Categorical
ariables were compared by the Fisher exact test. Continu-
us variables are presented as mean  1 SD or median with
nterquartile ranges and were compared by the Wilcoxon
wo-sample test. Survival estimates were created and dis-
layed as Kaplan-Meier curves, and compared using the
og-rank test. The influence of baseline variables on the
ine-month rates of angiographic restenosis in patients with
iabetes was evaluated with logistic regression, using entry
nd stay criteria of 0.20 and 0.10, respectively. In
ddition to randomization arm, the following baseline
linical, angiographic, and procedural variables were entered
nto the multivariate model: age, gender, current cigarette
se, hypertension, hyperlipidemia, prior MI, unstable an-
ina, creatinine clearance, left ventricular ejection fraction,
picardial vessel, lesion length, reference vessel diameter,
aseline minimal luminal diameter, stent length, maximum
graphic Features of Pooled Patients With
nts Non-Diabetic Patients
(n  996) p Value
62.56  11.1 0.58
74.8% 0.0001
66.6% 0.0001
64.7% 0.0328
30.3% 0.9441
4 56.04  9.89 0.0001
33.9% 0.68
41.7% 0.24
27.2% 0.43
31.1% 0.63
13.2  6.3 0.044
2.77  0.48 0.013
0.94  0.34 0.35ngio
Patie
318)
10.6
%
%
%
%
10.9
%
%
%
%
6.2
0.47
0.3466.1  10.6 0.89
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Paclitaxel-Eluting Stents in Diabetic Patients April 19, 2005:1172–9nflation pressure, ostial location, tortuosity, angulation,
alcification, and study stents implanted (yes vs. no).
ESULTS
aseline characteristics. As seen in Table 1, patients with
edically treated diabetes compared to those without dia-
etes were more often female, more commonly had hyper-
ension and hyperlipidemia, and had lower baseline left
entricular ejection fraction. Lesion length was also signif-
cantly greater and reference vessel diameter significantly
maller in patients with diabetes.
able 2. Baseline Demographic and Angiographic Features in th
Diabetic Pati
Paclitaxel-Eluting
Stent
(n  155)
Bare-
St
(n 
linical characteristics
Age, yrs 62.6  10.3 61.8 
Male gender 59.4% 67
Diabetes requiring insulin 32.9% 33
Hypertension 79.4% 82
Hyperlipidemia 77.0% 66
Prior myocardial infarction 28.4% 31
Left ventricular ejection fraction, % 53.1  10.7 53.4 
Unstable angina 40.6% 30
Target lesion vessel
Left anterior descending 36.4% 39
Left circumflex 28.6% 29
Right 35.1% 31
ngiographic features
Lesion length, mm 14.2  6.2 13.7 
Reference vessel diameter, mm 2.72  0.47 2.67 
Minimal luminal diameter, mm 0.91  0.34 0.92 
Diameter stenosis, % 66.3  10.9 65.7 
able 3. Procedural Outcomes in Patients Stratified by the Prese
Variables
Diabetic P
Paclitaxel-Eluting
Stent
(n  155)
Ba
(n
rocedural outcomes
n stents per patient (study vessel) 1.07  0.33 1.
Maximum device diameter, mm 3.12  0.43 3.
Maximum balloon/artery ratio 1.17  0.17 1.
Stent length, mm 22.3  9.33 22
Stent length lesion length ratio, median 1.46 (1.26–1.86) 1.56
Maximum device pressure, atm 15.0  2.8 15
Use of glycoprotein IIb/IIIa inhibitors 54.8%
Use of intravascular ultrasound 28.4%
ngiographic results
Final reference vessel diameter, mm 2.75  0.47 2.
Final minimal lumen diameter, mm
Analysis segment 2.20  0.49 2.
In-stent 2.62  0.42 2.
Final diameter stenosis, %
Analysis segment 19.97  10.1 20.
In-stent 4.55  10.7 4.58 Among patients with diabetes, the baseline demographic
nd angiographic features were similar in the paclitaxel-
luting and bare-metal stent groups, except that there were
lightly more patients with hyperlipidemia in the drug-
luting stent group (Table 2). Procedural parameters and
utcomes including number, mean length and diameter of
tents utilized, use of glycoprotein IIb/IIIa inhibitors, and
nal minimal luminal diameter and percent diameter ste-
osis were also similar (Table 3). Among patients without
iabetes, all baseline features, as well as procedural param-
ters and results, were similar in the paclitaxel-eluting and
ontrol stent arms.
domized Groups Stratified by the Presence of Diabetes
Non-Diabetic Patients
l
p Value
Paclitaxel-Eluting
Stent
(n  507)
Bare-Metal
Stent
(n  489) p Value
0.54 62.9  11.4 62.2  10.9 0.28
0.16 75.5% 74.0% 0.61
1.00 0% 0% —
0.47 62.9% 65.1% 0.31
0.03 68.1% 66.6% 0.22
0.62 31.2% 29.4% 0.58
2 0.83 55.9  9.7 56.2  10.1 0.66
0.06 34.3% 33.5% 0.84
0.64 41.1% 42.6% 0.65
1.00 29.1% 25.0% 0.15
0.55 29.8% 32.4% 0.41
0.46 13.1  6.3 13.2  6.2 0.73
0.44 2.77  0.47 2.78  0.49 0.70
0.88 0.92  0.33 0.95  0.34 0.12
0.63 66.6  10.6 65.6  10.6 0.12
f Diabetes Mellitus
ts Non-Diabetic Patients
etal
t
63) p Value
Paclitaxel-Eluting
Stent
(n  507)
Bare-Metal
Stent
(n  489) p Value
0.30 0.68 1.07  0.25 1.05  0.26 0.25
0.41 0.65 3.15  0.41 3.18  0.42 0.30
0.18 0.18 1.16  0.15 1.16  0.15 0.67
9.0 0.84 21.6  7.5 21.2  8.0 0.42
–2.04) 0.38 1.60 (1.3–2.13) 1.62 (1.29–2.11) 0.64
3.1 0.19 14.8  2.8 15.0  2.8 0.17
0.43 58.6% 58.9% 0.94
0.62 20.9% 23.3% 0.40
0.46 0.55 2.81  0.47 2.82  0.50 0.75
0.49 0.48 2.27  0.46 2.30  0.50 0.38
0.40 0.31 2.68  0.44 2.68  0.42 0.97
10.3 0.64 19.04  9.3 18.42  10.0 0.31e Ran
ents
Meta
ent
163)
11
.5%
.1%
.8%
.0%
.3%
11.
.1%
.5%
.0%
.5%
6.1
0.47
0.34nce o
atien
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Sten
 1
09 
14 
19 
.1 
(1.26
.4 
50.3%
25.8%
72 
17 
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50 
11.9 0.98 3.82  11.0 4.00  11.25 0.80
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April 19, 2005:1172–9 Paclitaxel-Eluting Stents in Diabetic Patientslinical outcomes. Among diabetics, the paclitaxel-
luting stent in comparison to the control bare-metal stent
educed the one-year rates of target lesion revascularization
TLR) by 65% and TVR by 53%, due to reductions in both
he need for repeat percutaneous intervention and bypass
raft surgery (Table 4). As a result, MACE rates were
educed by 44%; the rates of death, MI, and stent throm-
osis were similar between control and TAXUS stent. The
elative reductions in TLR and TVR were similar in
on-diabetic patients (Table 4).
ngiographic results. Pre-specified follow-up angiogra-
hy at nine months was completed in 136 of 189 patients
ith diabetes, and in 423 of 543 patients without diabetes
72.0% vs. 77.9%, respectively, p  0.54). In the diabetic
ubgroup, the paclitaxel-eluting stent reduced late loss and
ate loss index compared to the control stent, resulting in a
reater late minimal lumen diameter and lower diameter
tenosis (Table 5). As a result, binary restenosis in patients
ith diabetes was reduced by 84% within the stent (relative
isk 0.16 [0.06 to 0.45], p  0.0001) and by 81% over the
nalysis segment (0.19 [0.07 to 0.47], p  0.0001). The
aclitaxel-eluting stent also markedly reduced the frequency
f diffuse in-stent restenosis in patients with diabetes, such
hat when restenosis did occur, the lesions were significantly
horter. The relative reduction in restenosis seen with the
aclitaxel-eluting stent in diabetic patients was comparable
o non-diabetics (Table 5). Among patients with diabetes
ellitus, the most powerful determinate by logistic regres-
ion analysis of freedom from analysis segment restenosis
as randomization to the TAXUS stent rather than a
are-metal stent (odds ratio [95% confidence interval 0.06
o 0.34], p  0.0001).
mpact of type of diabetic treatment. In pooled analysis,
he one-year rate of MACE progressively increased from
atients without diabetes, to those managed with oral
edications, to those requiring insulin (13.4% vs. 19.6% vs.
6.2%, respectively, p  0.0003). The paclitaxel-eluting
tent reduced the one-year rates of MACE, target vessel
ailure, TLR, and TVR to a similar degree in diabetic
atients requiring insulin, those managed with oral agents
lone, and those without diabetes (Fig. 1). Similarly, in
atients treated with the control stent, angiographic reste-
osis rates (analysis segment) tended to be higher in
nsulin-requiring diabetics compared to diabetic patients
anaged with oral medications and non-diabetics (42.9%
s. 29.7% vs. 24.4%, respectively, p  0.17). Restenosis was
ignificantly reduced in all three groups with the paclitaxel-
luting stent (Fig. 2) such that the rate of restenosis was
imilar and independent of diabetic status or treatment type
7.7% vs. 5.8% vs. 8.5%, respectively, p  0.81). Among
atients treated with the paclitaxel-eluting stent, the late
oss and loss index were similar or lower among insulin-
equiring diabetics compared with those managed on oral
edications alone (Table 6). Ta
b
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revious studies of percutaneous intervention in diabetic
atients have consistently demonstrated an independent
ssociation of diabetes with adverse outcomes, including
reater rates of MACE, TLR and TVR, and restenosis
5–8,11–15). The smaller vessel size, longer lesion length,
nd greater plaque burden present in the diabetic patient
ay contribute to increased restenosis after stent implanta-
ion. In addition, acute results are often less optimal in the
iabetic, with less acute gain (16). The inferior acute gains
ay be due to greater plaque burden (16) or mediated, in
art, by vascular noncompliance. Moreover, neointimal
yperplasia is increased in the diabetic artery after coronary
ntervention, resulting in greater late in-stent lumen loss
17). It has been postulated that the hyperglycemic state
ay induce, alter, or accentuate the biologic mechanisms
hat contribute to the greater tissue proliferation and more
iffuse restenotic pattern seen with diabetes. Specifically,
ascular tissue thickening may be related to glycosylation of
ascular collagen and elastin (18,19). Regardless of the
echanisms, the presence of diabetes (especially insulin-
equiring diabetes) has been a consistent, independent
able 5. Angiographic Measures at Nine Months Stratified by th
Diabetic Patient
Paclitaxel-Eluting
Stent
(n  78)
Bare-M
Stent
(n  5
eference vessel diameter, mm 2.73  0.46 2.75  0
inimal luminal diameter, mm
Analysis segment 2.03  0.55 1.61  0
Proximal edge 2.52  0.55 2.46  0
In-stent 2.24  0.60 1.67  0
Distal edge 2.35  0.49 2.24  0
iameter stenosis
Analysis segment 25.78  15.31 41.68  1
Proximal edge 14.30  12.49 16.04  1
In-stent 18.04  16.79 39.64  2
Distal edge 7.35  9.39 11.17  1
ate loss, mm
Analysis segment 0.17  0.45 0.58  0
Proximal edge 0.14  0.42 0.28  0
In-stent 0.37  0.52 0.96  0
Distal edge 0.01  0.31 0.13  0
oss index
Analysis segment 0.12  0.37 0.50  0
In-stent 0.22  0.34 0.60  0
inary restenosis rate, %
Analysis segment 6.4% 34.5%
Proximal edge 1.3% 1.8%
In-stent 5.1% 31.6%
Distal edge 0.0% 3.6%
attern of restenosis, %
Focal 5.1% 6.9%
Diffuse 1.3% 22.4%
Proliferative 0.0% 3.4%
Total occlusion 0.0% 1.7%
ength of restenosed lesion, mm 8.51  2.80 14.49  4redictor of restenosis in nearly all previous stent trials. iIn the present analysis of 318 diabetic patients in the
AXUS-IV randomized trial, representing the largest re-
orted experience to date with drug-eluting stents in dia-
etics, the paclitaxel-eluting stent substantially reduced late
umen loss, late loss index, and restenosis compared with the
ontrol bare-metal stent. As a result, TAXUS stent implan-
ation resulted in significantly lower rates of TLR and TVR
n diabetics, with a reduction in the need for both repeat
ercutaneous coronary intervention and bypass surgery. The
elative and absolute magnitude of the benefit of the
aclitaxel-eluting stent in patients with diabetes was com-
arable to that in non-diabetics. Notably, luminal dimen-
ions at follow-up were greater with site-specific paclitaxel
reatment both within the stent and at the proximal and
istal edges. Moreover, diffuse in-stent restenosis was re-
uced in diabetic patients by more than 90% with the
aclitaxel-eluting stent, such that when angiographic reste-
osis did occur, it was predominantly focal in nature.
Importantly, the relative efficacy of the TAXUS stent in
nsulin-requiring diabetics in terms of reducing clinical and
ngiographic restenosis was similar to that in patients with
on–insulin-requiring diabetes. In insulin-requiring diabet-
sence of Diabetes
Non-Diabetic Patients
p Value
Paclitaxel-Eluting
Stent
(n  214)
Bare-Metal
Stent
(n  209) p Value
0.86 2.76  0.46 2.78  0.47 0.55
0.0001 2.03  0.55 1.70  0.59 0.0001
0.57 2.60  0.62 2.52  0.60 0.21
0.0001 2.27  0.58 1.77  0.63 0.0001
0.24 2.34  0.52 2.26  0.53 0.090
0.0001 26.48  15.5 39.26  18.08 0.0001
0.50 12.78  13.72 16.16  14.76 0.02
0.0001 17.20  18.07 36.59  19.4 0.0001
0.10 7.69  12.8 12.0  12.38 0.0005
0.0001 0.25  0.43 0.62  0.59 0.0001
0.085 0.15  0.42 0.27  0.49 0.009
0.0001 0.40  0.49 0.91  0.58 0.0001
0.09 0.07  0.42 0.19  0.43 0.007
0.0001 0.18  0.38 0.47  0.47 0.0001
0.0001 0.23  0.31 0.55  0.37 0.0001
0.0001 8.5% 24.4% 0.0001
1.00 3.4% 4.0% 0.80
0.0001 5.6% 22.5% 0.0001
0.17 0.9% 1.4% 0.68
0.72 6.5% 10.0% 0.22
0.0001 0.9% 12.0% 0.0001
0.18 0.5% 1.9% 0.21
0.43 0.9% 0.5% 1.00
0.01 9.60  4.82 14.90  9.30 0.003e Pre
s
etal
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.50
.66
.58
.70
.57
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.55
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.37cs, angiographic restenosis in the analysis segment was
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ared to the bare-metal stent, and the occurrence of diffuse
n-stent restenosis was reduced by more than 90%. Indeed,
mong patients treated with the paclitaxel-eluting stent,
oth the late loss and loss index were numerically lower in
nsulin-requiring diabetics compared to those managed with
ral agents alone, both within the stent and over the entire
nalysis segment. No safety concerns were noted in the overall
igure 1. One-year clinical outcomes among patients randomized to the
iabetic status and treatment type. (Upper left graph) Composite major
raph) Target vessel revascularization. (Lower right graph) Target lesion
igure 2. Nine-month rates of binary restenosis among patients random
tratified by diabetic status and treatment type. (Left) In-stent restenosis. (R
AXUS.iabetic cohort or insulin-requiring subgroup at one-year
ollow-up.
Previous studies examining the impact of drug-eluting stents
n diabetics have reported conflicting results. In the 73 diabetic
atients with focal lesions randomized to either the slow- or
oderate rate-release, polymer-based, paclitaxel-eluting stent
ersus a bare-metal stent in the TAXUS II trial, angiographic
inary restenosis rates were reduced from 20.5% with control
xel-eluting TAXUS stent versus a control EXPRESS stent, stratified by
se cardiac events. (Upper right graph) Target vessel failure. (Lower left
cularization.
o the paclitaxel-eluting TAXUS stent versus a control EXPRESS stent,paclitaized t
ight) Analysis segment restenosis. Black bars  control; open bars 
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he non–polymer-based local delivery of paclitaxel did not
ignificantly reduce restenosis in patients with or without
iabetes in a large randomized trial utilizing a different stent
latform (21). Nevertheless, it appears that utilization of an
ppropriate controlled-release mechanism such as a polymer
ay be required to deliver consistent paclitaxel dosing with
eliable pharmacokinetic drug delivery.
The reasons for the excellent outcomes with the
aclitaxel-eluting stent in diabetic patients are likely multi-
actorial. The primary mechanism of action of paclitaxel is
he prevention of microtubule depolymerization, which is
equired for mitosis to progress through anaphase (22).
ecause paclitaxel modulates cell mitogenesis downstream
rom Ras/Raf/MAP kinase, and independently from PI3
inase/PKb/mTOR signal-transduction pathways, it may
e particularly effective in the diabetic with insulin resis-
ance, inhibiting both insulin-dependent and -independent
athways that mediate neointimal hyperplasia (23–25).
oreover, in addition to being centrally involved in cell
ivision, microtubules control multiple other cellular func-
ions integral to restenosis, including cell signaling, activa-
able 6. Angiographic Outcomes in the Diabetic Subgroup Acco
Oral Hypoglycemic Agen
Paclitaxel-Eluting
Stent
(n  104)
Bare-Me
Stent
(n  10
arget lesion coronary artery
Left anterior descending 36.9% 38.0%
Left circumflex 25.2% 31.5%
Right 37.9% 30.3%
esion length, mm 13.83  6.63 13.96  6
eference vessel diameter, mm
Before 2.72  0.45 2.69  0
After 2.76  0.45 2.74  0
Follow-up 2.71  0.46 2.70  0
inimal luminal diameter, mm
Before 0.89  0.34 0.90  0
After
In-stent 2.60  0.41 2.58  0
Analysis segment 2.22  0.48 2.17  0
Follow-up
In-stent 2.18  0.58 1.68  0
Analysis segment 2.00  0.54 1.63  0
iameter stenosis, %
Before 67.2  11.4 66.5  1
After
In-stent 5.52  11.4 5.38  1
Analysis segment 19.9  10.1 21.2  9
Follow-up
In-stent 19.5  17.3 39.8  2
Analysis segment 26.1  15.7 41.1  2
ate loss
In-stent 0.40  0.52 0.96  0
Analysis segment 0.19  0.44 0.58  0
oss index
In-stent 0.24  0.35 0.59  0
Analysis segment 0.14  0.39 0.50  0ion, secretory processes, and migration (26–28). Because of Lhese multifunctional actions, paclitaxel may attenuate path-
ays specifically up-regulated in the diabetic restenotic
ascade. Finally, diabetics are known to have diffusely
iseased arteries; it is possible that relative lack of vessel
rauma at the edges with the TAXUS stent delivery system
s deployed in the TAXUS-IV trial and/or paclitaxel-
ediated cell-to-cell signaling processes contribute to the
reserved efficacy seen with this drug-eluting stent at the
tent margins in patients with diabetes (27,29).
The principal limitation of this study is that, although
andomization was stratified by diabetic status, the trial was
ot powered to show significant reductions in clinical and
ngiographic end points in patients with diabetes; thus, the
esults of this subset analysis, though pre-specified, must be
onsidered hypothesis-generating and not definitive. More-
ver, the number of patients in the insulin-requiring group
as relatively small (the likely reason why the reduction in
LR was only of borderline statistical significance with the
aclitaxel-eluting stent in this cohort), especially those with
ngiographic follow-up; greater experience with both drug-
luting stents is required to fully characterize the safety and
fficacy of these devices in insulin-requiring diabetics.
to Diabetic Treatment
nly Insulin ( Oral Medications)
p Value
Paclitaxel-Eluting
Stent
(n  51)
Bare-Metal
Stent
(n  54) p Value
0.97 35.3% 42.6% 0.55
0.36 35.3% 24.1% 0.28
0.31 29.4% 33.3% 0.68
0.88 15.10  5.3 13.29  6.1 0.11
0.62 2.70  0.50 2.65  0.40 0.51
0.79 2.73  0.52 2.67  0.41 0.52
0.92 2.80  0.47 2.72  0.45 0.58
0.85 0.96  0.34 0.96  0.35 0.98
0.64 2.65  0.43 2.57  0.32 0.27
0.46 2.18  0.51 2.17  0.48 0.86
0.0006 2.38  0.61 1.67  0.68 0.0005
0.008 2.10  0.58 1.58  0.62 0.005
0.67 64.6  9.75 64.1  11.8 0.82
0.92 2.59  8.82 3.00  12.5 0.84
0.35 20.05  10.1 19.1  11.2 0.65
0.0001 15.1  15.7 39.4  21.3 0.0001
0.0002 25.2  14.7 42.7  19.7 0.001
0.0001 0.30  0.52 0.96  0.60 0.0002
0.0001 0.14  0.47 0.58  0.57 0.005
0.0001 0.17  0.30 0.63  0.45 0.0004
0.0002 0.08  0.35 0.50  0.73 0.02rding
ts O
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tent thrombosis. Finally, the most complex diabetic pa-
ients were excluded from enrollment, including, for exam-
le, those with multivessel and diffuse disease. In this regard, a
arge-scale randomized trial funded by the National Heart,
ung, and Blood Institute will soon begin in which an
nselected diabetic cohort with multivessel disease will be
andomized to drug-eluting stent implantation (paclitaxel- or
irolimus-eluting) versus surgical revascularization.
onclusions and clinical implications. Despite the above
aveats, the one-year clinical and nine-month angiographic
esults after implantation of the polymer-based paclitaxel-
luting stent as shown in the TAXUS-IV trial suggest that
new standard has emerged for the percutaneous treatment
f diabetic patients. The TAXUS stent proved safe and
arkedly effective in reducing restenosis in the diabetic
atient, whether treated with oral hypoglycemic agents or
nsulin, such that for the first time the restenosis rate of
iabetic patients was reduced to that seen in the
on-diabetic.
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